Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia.
As physicians become more aware of the need to treat anaemia in their patients with cancer, they have to consider 2 treatment options: red blood cell transfusion or recombinant human erythropoietin [epoetin alfa; epoetin beta]. Healthcare systems are under increasing pressure to lower costs while ma...
| Publicado en: | Disease Management & Health Outcomes Vol. 8; no. 5; pp. 259 - 273 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Nov2000
|
| Acceso en línea: | Ver este registro en EBSCOhost |